The known knowns and known unknowns of vaccine-induced thrombotic thrombocytopaenia
JD McFadyen, K Peter - 2021 - academic.oup.com
2021•academic.oup.com
The COVID-19 pandemic has, to date, resulted in over 200 million infections and over 4.25
million deaths and continues to significantly disrupt health systems and societies worldwide.
However, in a remarkable triumph of medical science, a number of highly effective vaccines
have been developed in a previously inconceivable short time period and are now being
delivered globally. A significant issue to emerge in the midst of such a large-scale
vaccination effort has been the recognition of rare adverse events such as vaccine-induced …
million deaths and continues to significantly disrupt health systems and societies worldwide.
However, in a remarkable triumph of medical science, a number of highly effective vaccines
have been developed in a previously inconceivable short time period and are now being
delivered globally. A significant issue to emerge in the midst of such a large-scale
vaccination effort has been the recognition of rare adverse events such as vaccine-induced …
The COVID-19 pandemic has, to date, resulted in over 200 million infections and over 4.25 million deaths and continues to significantly disrupt health systems and societies worldwide. However, in a remarkable triumph of medical science, a number of highly effective vaccines have been developed in a previously inconceivable short time period and are now being delivered globally. A significant issue to emerge in the midst of such a large-scale vaccination effort has been the recognition of rare adverse events such as vaccine-induced thrombotic thrombocytopaenia (VITT), which has been predominantly associated with the adenovirus vector vaccines, ChAdOx1 nCoV19 (Oxford/Astra-Zeneca) and the Ad26. COV2. S COVID-19 (Janssen/Johnson & Johnson) vaccine. 1–3
Oxford University Press